
Pessimistic Dogs Are Better at Smelling Cancer—And Other Keys to Disease-Sniffing Success
Cancer can change a person's 'volatilome,' the unique set of volatile organic compounds found in breath, sweat, blood and urine. Billy and her cohort have learned to sniff out these subtle scent cues in masks worn by people with cancer diagnoses. Researchers are also studying how dogs can detect diseases such as COVID and malaria, as well as psychological conditions, including post-traumatic stress disorder.
Scientists discovered dogs' powerful disease-smelling skills in 1989, when a dog detected cancer in its handler. But clinicians still do not routinely use dogs for diagnosis. Besides the obvious logistical challenges, dogs vary greatly in their olfactory accuracy. Researchers are increasingly finding that disease-sniffing prowess may come down to individual dogs' personality—and how well their handlers know them. New research efforts are focused on figuring out which dogs would be best for the job and on interpreting dogs' behaviors during a smell test.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Sharyn Bistre Dabbah, a veterinary scientist now at the University of Bristol in England, set out with colleagues at the U.K. charity Medical Detection Dogs to learn how the animals' personalities—especially their level of optimism or pessimism—affect disease-detection skills. Their results appeared recently in PLoS One.
The researchers first showed the dogs what lay behind two screens at one end of a room: a 'positive' location with a tasty treat and a 'negative' one with an empty bowl. On subsequent visits to the room, the dogs typically bounded happily toward the former but trotted very slowly when they went to check out the latter—or simply didn't go there at all.
The scientists then placed bowls behind two new screens between the positive and negative spots, and they classified the dogs as 'optimistic' or 'pessimistic' based on how quickly they investigated these new locations.
Next, the team evaluated how accurately each dog could pick out a disease scent it was trained to detect among other smells. On average, the pessimistic dogs turned out to be more discerning. Pessimistic dogs are more cautious, and 'a more cautious dog might be better at not making mistakes,' Dabbah says.
Other personality traits also play a role, says Clara Wilson, who researches disease- and stress-sniffing dogs at the University of Pennsylvania. Dogs that enjoy the thrill of a hunt—and thrive while searching for missing people or hidden bombs—might find sniffing through disease samples again and again rather repetitive. 'We want a dog that doesn't get frustrated. They [should] find it rewarding, even though it may be less exciting,' Wilson explains.
Handlers' interpretations of dog behavior can also skew detection outcomes, says Akash Kulgod, co-founder of Dognosis, the Bengaluru-based start-up that trained Billy. Instead of teaching dogs to perform a specific behavior such as sitting or barking when they pick up an assigned scent—a process that takes extra time and can lead to dogs 'lying' for treats—Kulgod and his team directly analyze each dog's natural body language. Based on how confidently the dogs move, as analyzed with computer vision–based machine-learning tools, the team can spot successful detections. 'One of our dogs sniffs and then very confidently somersaults to go to the feeder,' Kulgod says. 'They each have their own unique quirks—but all of it can be quantified because it's all related to this reward expectation that you have from the past sessions.'
In a pilot study with 200 test samples involving 10 cancer types, presented at this year's American Society of Clinical Oncology conference, Dognosis dogs detected 96 percent of cancers. Next, the Dognosis team will scale up its study with 1,500 test samples.
Doctors currently diagnose many kinds of cancers by using a combination of blood tests and biopsies. Researchers are always on the lookout for less invasive methods—including options directly involving our canine companions, as well as electronic noses inspired by them. Dogs can currently outperform electronic sniffers. But this primacy may not last, according to Andreas Mershin, chief science officer at the Boston-based start-up RealNose.ai. He and his colleagues are developing electronic noses to sniff urine samples for prostate cancer and other diseases. If machine olfaction eventually surpasses dogs' abilities, it could help tackle the scalability problem—and give the animals a break.
Mershin's team put mammalian smell receptors on an electronic chip and used machine-learning algorithms to interpret the output. The technique focuses on broader patterns among detected molecules rather than categorizing them individually.
Dogs don't tick off a list of molecules in their heads, either; they just 'know' what cancer smells like. This helps them to sense it accurately no matter which organ it is from or what the patient ate before giving their breath sample. 'The dogs can generalize. They don't care about the font in which you write the scent; they just interpret it correctly,' Mershin says.
In a study published in PLoS One, Mershin and his team used machine-learning models to spot and analyze patterns of different odorants in urine samples from confirmed prostate cancer patients. Their findings, which built on work with diagnosis data from Medical Detection Dogs, suggest that focusing on this type of 'scent character' might work as a scalable alternative to dogs, even if it's currently much slower.
Meanwhile, back on the test platform, floppy-eared Billy quickly detects the subtle scent of cancer in one of the masks she has been sniffing—and confidently bounds back to get her reward. Such tests show strong potential, says postdoctoral researcher Amritha Mallikarjun of the University of Pennsylvania: 'The dogs, because of their amazing sense of smell and detection capabilities, are demonstrating to us what technology could look like 10 to 15 years from now.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
10 minutes ago
- USA Today
Gunman in CDC shooting blamed depression on COVID vaccine: Reports
The shooting "compounds months of mistreatment, neglect, and vilification that CDC staff have endured," a union representing CDC staff said in a statement. The gunman who opened fire on the headquarters of the Centers for Disease Control and Prevention in Atlanta, killing a police officer and rocking the medical research community, believed he suffered depression linked to the COVID-19 vaccine, multiple outlets reported. Patrick Joseph White, 30, who was found dead after police say he opened fire on CDC buildings near Emory University, had fixated on the COVID-19 vaccine and believed it caused him to become depressed and suicidal, the Associated Press, CNN and ABC News reported, citing law enforcement sources. 'He was very unsettled, and he very deeply believed that vaccines hurt him and were hurting other people,' Nancy Hoalst, a neighbor who lived near White told the Atlanta Journal-Constitution. 'He emphatically believed that.' The DeKalb County Police Department did not immediately respond to USA TODAY's request for comment. Authorities say White opened fire outside the CDC headquarters in downtown Atlanta, hitting at least four buildings on the afternoon of Aug. 8. DeKalb County Police Officer David Rose, a veteran who graduated from the police academy in the spring, was killed responding to the shooting, officials said. White was found dead on the second floor of a building across the street from the CDC campus. It remains unclear if he was shot by law enforcement or if his wounds were self inflicted, authorities said. An investigation into the shooting is underway and the Georgia Bureau of Investigations said its probe would "take an extended period of time." CDC union says shooting was 'deliberate,' demands more security In the wake of the deadly shooting, a union representing CDC employees said in a statement said the incident was not random, adding that it "compounds months of mistreatment, neglect, and vilification that CDC staff have endured." "The deliberate targeting of CDC through this violent act is deeply disturbing, completely unacceptable, and an attack on every public servant," said the American Federation of Government Employees, Local 2883. "Early reports indicate the gunman was motivated by vaccine disinformation, which continues to pose a dangerous threat to public health and safety." The union also demanded flexible leave and remote work options for CDC employees, as well as more perimeter security on all campuses until a full investigation is completed. RFK Jr., outspoken critic of COVID vaccines, issues statement on shooting Robert F. Kennedy Jr., a vaccine skeptic who has criticized the COVID-19 vaccine and the CDC, said in a statement that he was "deeply saddened by the tragic shooting." "We know how shaken our public health colleagues feel today," wrote Kennedy, the secretary of the Department of Health & Human Services, which oversees the CDC, on X. "No one should face violence while working to protect the health of others." Last week, Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology used in the two most common COVID-19 shots "ineffective" and claiming it poses more risks than benefits. Clinical trials for the COVID-19 vaccines involving tens of thousands of people have shown the vaccines are safe and effective, according to the CDC. Contributing: Jeanine Santucci


Politico
38 minutes ago
- Politico
The CDC shooting aftermath
Driving the Day GUNMAN HITS THE CDC — CDC employees across all of the agency's campuses will be teleworking today, agency leadership told employees, according to a partial recording of a staff call obtained by POLITICO, after a gunman shot multiple rounds into four buildings on the agency's main campus in Atlanta on Friday. The agency is also offering administrative leave for employees who had to shelter in place. The campus saw some facility damage, including broken locks and doors, as law enforcement worked to clear and secure the area, CDC officials said on the call. Media outlets have reported that the gunman believed the Covid-19 vaccine had made him sick, citing law enforcement. A police officer was killed while responding to the incident, though no CDC staff were harmed. The agency is conducting a 'full security assessment,' agency Director Susan Monarez said on the call. 'There was a lot that went right, there was a lot that we want to make sure that we put in place so that when you do return, that everyone can feel safe and supported,' Monarez said. The backlash: Dr. Elizabeth Soda, an infectious disease doctor with the CDC's Center for Emerging and Zoonotic Infectious Diseases, called for Health Secretary Robert F. Kennedy Jr. to resign on Sunday. 'I am enraged at Robert F. Kennedy Jr.,' said Soda, noting she was speaking in her 'own private capacity.' 'As health secretary, his lies are costing people their lives. His dangerous rhetoric is making Americans sicker as scientific decision-making is destroyed.' Former U.S. Surgeon General Jerome Adams also criticized Kennedy's response, calling it 'tepid' and too slow. 'How you respond to a crisis defines a leader, and quite frankly, Secretary Kennedy has failed in his first major test in this regard,' Adams told CBS's Margaret Brennan on 'Face the Nation.' Kennedy addressed the incident in a post on social media platform X on Saturday. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose — even in moments of grief and uncertainty,' he wrote. He also addressed agency staff in an email sent to CDC employees Saturday. An HHS spokesperson did not respond to a request for comment. Background: The Georgia Bureau of Investigation said 30-year-old Patrick Joseph White, of Kennesaw, Georgia, shot at the agency complex. 'He very deeply believed that vaccines had hurt him, and that they were hurting other people,' one of White's neighbors, Nancy Hoalst, told The New York Times on Saturday. DeKalb County police officer David Rose was shot and killed while responding to the attack. He was 33, had two children, and his wife was pregnant with a third. Monarez noted on the call that the agency is working to set up a donation for Rose's family. Key context: The shooting comes amid an already tumultuous time for CDC staff. Hundreds of agency employees received termination notices in April, but some were sporadically rehired. The Trump administration has also proposed slashing the agency's budget by roughly half. Kennedy has repeatedly raised concerns over the Covid vaccine's safety. Since he began leading HHS in February, the CDC has stopped recommending the vaccine for healthy pregnant people and narrowed the recommendations for healthy children. Kennedy said earlier this week that HHS would halt $500 million in funding for mRNA research, the technology used to create the first Covid vaccines, citing safety concerns. Many public health experts pushed back on that decision. WELCOME TO MONDAY PULSE. We're closely watching for the second MAHA report this week. Any intel on timing or contents? Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. Industry Intel NEW PLAN FOR INDIRECT COSTS — Academia has a counteroffer in the standoff between the Trump administration and universities over grant funding, POLITICO's Erin Schumaker reports. The federal government has long provided grantees with funding for administrative and facilities costs on top of research awards. But now, allies of President Donald Trump accuse the schools of using the payments as slush funds to pursue progressive causes like diversity, equity and inclusion. The universities deny misusing those funds, but to placate Trump, they're proposing the establishment of a more transparent model for recouping overhead costs. Currently, those fees are negotiated separately with each institution and can vary widely. At stake is more than $4 billion in funding. Losing that money would slow the search for breakthroughs in health and science and enable foreign rivals to catch up, the scientific community says. A federal district court judge blocked the administration's plan to cap the fees at 15 percent in March, although the administration has appealed. Charting a new path: 'It's been made extremely clear to us from day one by members of Congress that if we don't do something, somebody else will,' Kelvin Droegemeier, a professor at the University of Illinois at Urbana-Champaign who's spearheading the effort on behalf of a coalition of universities and research institutes, told POLITICO. 'They said continuing forward with the current model is not in the cards. We took it to mean we could help be a part of that change or wait for it to happen,' said Droegemeier, who led the White House Office of Science and Technology Policy during Trump's first term. The group proposes a Financial Accountability in Research, or FAIR, plan, which would consist of a detailed accounting of indirect project costs and a shorter, simpler fixed percentage of a project's budget for research organizations to recoup facilities and administrative expenses. The model is designed to show the costs of conducting research so the government and lawmakers can choose what to fund. What's next: Senate Appropriations Chair Susan Collins (R-Maine), who has protested the administration's cap because it would hurt universities in her state, floated the new model to NIH Director Jay Bhattacharya at a budget hearing in June, calling it 'far fairer' than Trump's flat rate and saying she believed it would 'increase accountability.' Talks are expected to ramp up when Congress returns from recess next month. AROUND THE AGENCIES GUESS WHO'S BACK — The FDA's top vaccine regulator, who was pushed out roughly two weeks ago under pressure from the White House, has been reinstated, POLITICO's David Lim reports. After Commissioner Marty Makary requested the return of Dr. Vinay Prasad to his job regulating biologics and vaccines, the White House decided the agency could bring him back after reviewing Prasad's past remarks highlighted by far-right provocateur Laura Loomer last month, according to a person familiar with the decision and granted anonymity to discuss the decision. 'At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,' HHS spokesperson Andrew Nixon said. HHS declined to answer additional questions about Prasad's reinstatement. Why it matters: The return of Prasad marks a personnel victory for HHS Secretary Robert F. Kennedy Jr. and Makary, who opposed his dismissal. In the days after Prasad's ouster, Makary told reporters he encouraged Prasad to reconsider his exit from government. Loomer immediately slammed the decision to rehire Prasad on social media platform X, describing him as a progressive and referring to his past remarks criticizing President Donald Trump. 'In the coming weeks, I will be ramping up my exposes of officials within HHS and FDA so the American people can see more of the pay for play rot themselves and how rabid Trump haters continue to be hired in the Trump administration,' Loomer posted Saturday. 'There are several Senate Confirmation hearings coming up and I have multiple oppo books ready for distribution!' Sarepta Therapeutics: It's unclear what Prasad's return will mean for Sarepta Therapeutics, which sparred with the FDA center that regulates its Duchenne muscular dystrophy treatment, Elevidys, in the days before he was removed from the job last month. Industry Intel THE IMPACT OF KENNEDY'S mRNA MOVE — Messenger RNA technology, and its potential in cancer treatment and prevention, has excited scientists for years. Now, following HHS Secretary Robert F. Kennedy Jr.'s decision to yank half a billion dollars in federal funding for mRNA vaccine projects, researchers and drugmakers worry that potential will be curtailed, POLITICO's Lauren Gardner reports. Key context: The rapid development and deployment of mRNA vaccines during the pandemic stoked enthusiasm for the technology's potential to revolutionize cancer treatment. The much faster manufacturing process and the mRNA platform's ability to instruct the immune system to attack problem proteins make it possible to custom-tailor therapies to fight a person's unique tumor. Dozens of treatments are being studied or already in the pipeline. But scientists and industry executives say Kennedy's discouragement of mRNA vaccines for respiratory diseases could dampen investors' enthusiasm for U.S. companies pursuing drug candidates for cancers and rare genetic diseases that have few therapeutic options. And they fear those firms and researchers might decide to move overseas to countries hungry for their expertise — including places like China that could limit Americans' access to treatments developed within their borders. 'If there was a treatment out there for pancreatic cancer but we couldn't get access to it, how would that make you feel if you had a loved one with pancreatic cancer?' said Kate Broderick, chief innovation officer at Maravai LifeSciences, which makes components for drugs and therapies. 'And that is a genuine reality of these cancellations.' An HHS spokesperson called the industry's assessment of potential fallout from Kennedy's mRNA decisions 'false,' adding that other uses of the technology weren't affected by Tuesday's announcement. WHAT WE'RE READING The Wall Street Journal's Liz Essley Whyte reports on how Robert F. Kennedy Jr. is trying to bring MAHA to Alaska. The Washington Post's Sabrina Malhi reports on growing anti-sunscreen sentiment on social media that's worrying dermatologists.


Newsweek
41 minutes ago
- Newsweek
Trump's Ex-Surgeon General Attacks Vaccine Cuts: 'People Are Going To Die'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump's former Surgeon General Jerome Adams has warned that "people are going to die" if the United States cuts funding for mRNA vaccine development. It comes after Health and Human Services Secretary Robert F. Kennedy Jr. announced last week that his department would terminate 22 Biomedical Advanced Research and Development Authority (BARDA) investments in mRNA vaccine development, representing nearly $500 million in federal funding. He said the decision was taken after reviews showed mRNA vaccines "failed protect effectively against upper respiratory infections like COVID and flu." Newsweek contacted the United States Department of Health and Human Services (HHS) for comment via email outside of regular working hours. Former Surgeon General Jerome Adams speaking at the White House in April 2020. Former Surgeon General Jerome Adams speaking at the White House in April 2020. AP Why It Matters Kennedy has been a longtime vaccine critic, and questioned their effectiveness on numerous occasions. His tenure as the head of HHS has seen top vaccine experts, food safety supervisors and other public-health officials either resign or be ousted. The 22 projects are led by major pharmaceutical companies, including Pfizer and Moderna, and aim to develop vaccines against the flu, COVID-19 and H5N1. mRNA technology, which underpins these vaccines, is widely credited with helping slow the spread of the coronavirus during the 2020 pandemic. Infectious-disease specialists have also warned that future pandemics will be harder to stop without the help of mRNA. What To Know Adams, who served in Trump's first administration, said in an interview with CBS News on Sunday that mRNA technology accelerated vaccine development by an estimated 18 to 24 months. He added that "by the most conservative estimates, at least 2 million lives were saved" during the pandemic because of mRNA vaccines. "It's a natural molecule that's in all of our bodies. It's like a recipe card that tells your body how to make a protein," he said. "And this new idea, again, helps us develop vaccines and new treatments for everything from cancer, melanoma - which my wife has - to HIV, to better flu vaccines." He added: "These are advances that are not going to happen now... people are going to die because we're cutting short funding for this technology." Several other infectious disease experts have also spoken out against Kennedy's decision. Rick Bright, the former director of BARDA, said on X: "A bad day for science, and huge blow to our national security. This decision will have dangerous repercussions." Dr. Thomas A. Russo, an expert in infectious diseases, told Newsweek that Kennedy's decision was "shortsighted," and said mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What People Are Saying RFK Jr. said on X last week: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." Infectious diseases expert Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, who specializes in pandemic preparedness, told Newsweek: "RFK's actions are completely devoid of value. They are only designed to serve more distrust of a proven and valuable vaccine technology. The repercussions of this decision will serve only to diminish the resiliency of the United States, and the world, to infectious disease threats." What Happens Next In his statement, Kennedy urged the department to shift from mRNA vaccines and "invest in better solutions," but did not specify alternatives. Lawmakers, public-health officials, and industry leaders are expected to press HHS for detailed timelines and alternative research investments options.